Fingerprint
Dive into the research topics where Karilyn Larkin is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Leukemia-driven expansion of type 3 innate lymphoid cell facilitates a pro-tumoral microenvironment in acute myeloid leukemia
Dinh, T. T. T., Lordo, M. R., Zhang, A. Y., Goda, C., Shilo, N., Altynova, E., Ruesch, M., Kronen, P., Broughton, M., Jeremy, E., Sellers, V. L., Zhang, X., Larkin, K. T., Collins, P. L., Dorrance, A. M., Freud, A. G., Oakes, C. C. & Mundy- Bosse, B. L., Feb 2026, In: Leukemia. 40, 2, p. 325-338 14 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AML
Jain, J., Pugh, K., Handa, S., Dvorak-Kornaus, K. M., Zhao, Q., Walter, R. B., Cook, R., Saultz, J., Swords, R., Li, J., Laszlo, G. S., Grieselhuber, N. R., Mims, A. S., Larkin, K. T. M., Sahasrabudhe, K., Blachly, J. S., Behbehani, G. K., Eisfeld, A. K., Long, M. & Srisuwananukorn, A. & 2 others, , Feb 2026, In: Blood Neoplasia. 3, 1, 100171.Research output: Contribution to journal › Article › peer-review
Open Access -
Successful engraftment in myeloablative transplant with cadaveric bone marrow after sudden unavailability of living donor
Vasu, S., Wall, S., Larkin, K., Munjal, S., de Lima, M. & Sanchez-Petitto, G., Feb 24 2026, In: Blood Advances. 10, 4, p. 951-952 2 p.Research output: Contribution to journal › Article › peer-review
Open Access -
CD37 in acute myeloid leukemia: a novel surface target for drug delivery
Jeremy, E., Artiga, E., Elgamal, S., Cheney, C., Eicher, D., Zalponik, K., Orwick, S., Mao, C., Wasmuth, R., Harrington, B., Mustonen, A., Beshay, P., Halley, P., Castro, C., Williams, K., Hing, Z., Chen, T., Lucas, C., Vantangoli, N. J. & Lapalombella, R. & 7 others, , Jan 14 2025, In: Blood Advances. 9, 1, p. 1-14 14 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Link opens in a new tab Scopus citations -
Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies
Caputo, J., Peddireddi, A., Bhatta, S., Huang, Y., Bezerra, E., Brammer, J., Larkin, K., Mims, A., Vasu, S., Wall, S. & Choe, H., 2025, In: Leukemia and Lymphoma. 66, 1, p. 131-138 8 p.Research output: Contribution to journal › Article › peer-review
Open Access11 Link opens in a new tab Scopus citations